BARI 2D Publications


  1. Singh PP, Abbott JD, Lombardero MS, Sutton-Tyrrell K, Woodhead G, Venjitachalam L, Tsapatsaris NP, Piemonte TC, Lago RM, Rutter MK, Nesto RW, and the BARI 2D Investigators. The Prevalence and Predictors of an Abnormal Ankle-Brachial Index in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Diabetes Care. 2011: 34 (2):464-467.


  2. Tamis-Holland JE, Lu J, Bittner V, Magee MF, Lopes N, Adler D, Kip KE, Schwartz L, Groenewoud Y, Jacobs AK, for the BARI 2D Study Group. Sex, Clinical Symptoms, and Angiographic Findings in Patients with Diabetes Mellitus and Coronary Artery Disease (from the Bypass Angioplasty Revascularization Investigation BARI 2D). American Journal of Cardiology. 2011:107(7):980-985.


  3. Brooks MM, Chung S-C, Helmy T, Hillegass WB, Escobedo J, Melsop KA, Massaro EM, McBane RD, Hyde P, Hlatky MA and the BARI 2D Study Group. Health Status after Treatment for Coronary Artery Disease and Type 2 Diabetes in the BARI 2D Trial. Circulation 2010; 122:1690-1699.


  4. Grogan M, Jenkins M, Sansing VV, Macgregor J, Brooks MM, Julien-Williams P, Amendola A, Abbott JD. Health Insurance Status and Control of Diabetes and Coronary Artery Disease Risk Factors on Enrollment into the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Diabetes Educ. 2010; 36:774-783.


  5. Wall BM, Hardison RM, Molitch ME, Marroquin OC, McGill JB, August PA; for the BARI 2D Study Group. High Prevalence and Diversity of Kidney Dysfunction in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The BARI 2D Baseline Data. Am J Med Sci. 2010; 339:401-410.


  6. Rana JS, Hardison RM, Pop-Busui R, Brooks MM, Jones TLZ, Nesto RW, Bourassa MG, and the BARI 2D Investigators. Resting Heart Rate and Metabolic syndrome in Patients with Diabetes and Coronary Artery Disease in Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Preventive Cardiology 2010; 13:112-116.


  7. Thomas SB, Sansing VV, Davis A, Magee M, Massaro E, Srinivas VS, Helmy T, Desvigne-Nickens P, Brooks MMB, and BARI 2D Study Group. Racial Differences in the Association between Self-Rated Health Status and Objective Clinical Measures among Participants in the BARI 2D Trial. Am J Public Health: 2010; 100Suppl 1: S269-276.


  8. Hlatky MA, Chung S-C, Escobedo J, Hillegass WB, Melsop K, Rogers W, Brooks MM for the BARI 2D Study Group. The Effect of Obesity on Quality of Life in Patients with Diabetes and Coronary Artery Disease. Am Heart J: 2010; 159:292-300.


  9. Albu JB , Lu J, Mooradian AD, Krone RJ, Nesto RW, Porter MH, Rana JS, Rogers WJ, Sobel BE, Gottlieb SH and for the BARI 2D Study Group. Relationships of Obesity and Fat Distribution with Atherothrombotic Risk Factors: Baseline Results From the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Obesity: (Silver Spring) 2009; doi:10.1038/oby.2009.339.


  10. Escobedo J, Rana JS, Lombardero MS, Albert SG, Davis, AM, Kennedy FP, Mooradian AD, Robertson DG, Srinivas VS, Gebhart SSP, and for the BARI 2D Study Group. Association between Albuminuria and Duration of Diabetes and Myocardial Dysfunction and Peripheral Arterial Disease Among Patients with Stable Coronary Artery Disease in the BARI 2D Study. Mayo Clinic Proceedings 2010 85(1):41-46. PMCID: PMC2800289


  11. McBane RD, Hardison RM, Sobel BE, BARI 2D Study Group. Comparison of Plasminogen Activator Inhibitor-1, Tissue Type Plasminogen Activator Antigen, Fibrinogen, and D-Dimer Levels in Various Age Decades in Patients With Type 2 Diabetes Mellitus and Stable Coronary Artery Disease (from the BARI 2D Trial) American Journal of Cardiology 2010; 105(1):17-24. PMCID: PMC2814593


  12. Hlatky MA, Boothroyd DB, Melsop KA, Kennedy L, Rihal C, Rogers WJ, Venkitachalam L, Brooks MM, for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group. Economic Outcomes of Treatment Strategies for Type 2 Diabetes Mellitus and Coronary Artery Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial. Circulation 2009; 120:2550-2558. PMCID: PMC2783640


  13. Chaitman BR, Hardison RM, Adler D, Gebhart S, Grogan M, Ocampo S, Sopko G, Ramires JA, Schneider D, Frye RL, and the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group. The Bypass Angioplasty Revascularization Investigation 2 Diabetes Randomized Trial of Different Treatment Strategies in Type 2 Diabetes Mellitus with Stable Ischemic Heart Disease: Impact of Treatment Strategy on Cardiac Mortality and Myocardial Infarction. Circulation 2009; 120: 2529 - 2540. PMCID: PMC2830563


  14. Pop-Busui R, Lombardero M, Lavis V, Forker A, Green J, Korytkowski M, Sobel BE, Jones TLZ, and the BARI 2D Study Group. Relation of Severe Coronary Artery Narrowing to Insulin or Thiazolidinedione Use in Patients with Type 2 Diabetes Mellitus (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes Study). American Journal of Cardiology 2009; 104(1):52-58. PMCID: PMC2756995


  15. The BARI 2D Study Group. A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease. New England Journal of Medicine 2009; 11; 360(24):2503-15. PMCID: PMC2863990


  16. Kim LJ, King SB III, Kent K, Brooks MM, Kip KE, Abbott JD, Jacobs AK, Rihal C, Hueb WA, Alderman E, Pena Sing IR, Attubato MJ, Feit F for the BARI 2D Study Group. Factors Related to the Selection of Surgical Versus Percutaneous Revascularization in Diabetic Patients with Multivessel Coronary Artery Disease in the BARI 2D Trial. Journal of the American College of Cardiology: Cardiovascular Interventions 2009; 2:384-392.


  17. Schneider DJ, Hardison RM, Lopes N, Sobel BE, Brooks MM and the Pro-Thrombosis Ancillary Study Group. Association Between Increased Platelet P-Selectin Expression and Obesity in Patients with Type 2 Diabetes: A BARI 2D substudy. Diabetes Care: 2009; 32:944-949. PMCID: PMC2671133


  18. Pop-Busui R, Lu J, Lopes N, Jones TLZ for the BARI 2D Study Group. Prevalence of Diabetic Peripheral Neuropathy and Relation to Glycemic Control Therapies at Baseline in the BARI 2D Cohort. Journal of the Peripheral Nervous System 2009; 14:1–13. PMCID: PMC2692660


  19. Schwartz L, Kip KE, Alderman E, Lu J, Bates ER, Srinivas V, Bach RG, Mighton LD, Feit F, King SB III, Frye RL for the BARI 2D Study Group. Baseline Coronary Angiographic Findings in the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial (BARI 2D). American Journal of Cardiology 2009; 103(5):632-638.


  20. Pambianco G, Lombardero M, Bittner V, Forker A, Kennedy F, Krishnaswami A, Mooradian AD, Pop-Busui R, Rana JS, Rodriguez A, Steffes M, Orchard TJ. Control of Lipids at Baseline in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Preventive Cardiology 2009; 12:9-18. PMCID: PMC2717619


  21. Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group. Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. American Heart Journal 2008; 156(3):528-536, 536.e1-5. PMCID: PMC2701266


  22. Iskandrian AE, Heo J, Mehta D, Tauxe EL, Yester M, Hall MB, MacGregor JM. Gated SPECT Perfusion Imaging for the Simultaneous Assessment of Myocardial Perfusion and Ventricular Function in BARI 2D: An Initial Report from the Nuclear Core Laboratory. Journal of Nuclear Cardiology. 2006; 13:83-90.


  23. Detre KM, Frye RL, Genuth S, guest editors. A Symposium: Treatment of Coronary Artery Disease and Type 2 Diabetes: The Rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. American Journal of Cardiology 2006; 97(suppl 12A):1G-65G.


  24. Steiner G for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial Investigators. Statement of the Problem. American Journal of Cardiology 2006; 97(suppl 12A):3G-8G.


  25. Brooks MM, Frye RL, Genuth S, Detre KM, Nesto R, Sobel BE, Kelsey SF, Orchard TJ for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial Investigators. Hypotheses, Design and Methods for the Bypass Angioplasty Revascularization Investigation 2 (BARI 2D) Trial. American Journal of Cardiology 2006; 97(suppl 12A):9G-19G.


  26. Magee MF, Isley WL for the BARI 2D Trial Investigators. Rationale, Design, and Methods for Glycemic Control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. American Journal of Cardiology 2006; 97(suppl 12A):20G-30G.


  27. Barsness GW, Gersh BJ, Brooks MM, and Frye RL for the BARI 2D Trial Investigators. Rationale for the Revascularization Arm for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. American Journal of Cardiology 2006; 97(suppl 12A):31G-40G.


  28. Albu J, Gottlieb SH, August P, Nesto RW, and Orchard TJ for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial Investigators. Modifications of Coronary Risk Factors. American Journal of Cardiology 2006; 97(suppl 12A):41G-52G. PMCID: PMC2670550


  29. Sobel BE for the BARI 2D Trial Investigators. Ancillary Studies in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial: Synergies and Opportunities. American Journal of Cardiology 2006; 97(suppl 12A):53G-58G.


  30. Hlatky MA, Melsop KA, and Boothroyd DB for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial Investigators. Economic Evaluation of Alternative Strategies to Treat Patients with Diabetes Mellitus and Coronary Artery Disease. American Journal of Cardiology 2006; 97(suppl 12A):59G-65G.


  31. Sobel BE, Frye R, Detre KM. Burgeoning Dilemmas in the Management of Diabetes and Cardiovascular Disease: Rationale for the BARI 2D Trial. Circulation 2003; 107(4):636-642.



University of Pittsburgh Epidemiology Data Center
© All Rights Reserved Worldwide